Clearmind Medicine Inc (CMND)

May 12, 2026, 8:41 AM EDT - 1 day ago

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

May 11, 2026, 7:55 AM EDT - 2 days ago

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

2026-05-05T12:59:55.000Z - 7 days ago

Clearmind Medicine files European patent application for psychedelic compounds

May 5, 2026, 8:50 AM EDT - 7 days ago

Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD

2026-04-30T21:03:58.000Z - 12 days ago

Clearmind Medicine files to sell 22.63M common shares for holders

2026-04-27T11:48:40.000Z - 16 days ago

Clearmind announces evaluation of CMND-100 for breakthrough therapy designation

Apr 27, 2026, 7:41 AM EDT - 16 days ago

Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation

Apr 20, 2026, 4:03 PM EDT - 22 days ago

Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care

Apr 20, 2026, 7:15 AM EDT - 23 days ago

Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial

2026-04-16T15:26:52.000Z - 26 days ago

Clearmind announces DSMB recommendation to continue CMND-100 trial

Apr 15, 2026, 7:30 AM EDT - 4 weeks ago

Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial

2026-04-14T11:40:10.000Z - 4 weeks ago

Clearmind Medicine announces CMND-100 meets primary endpoint

Apr 14, 2026, 7:32 AM EDT - 4 weeks ago

Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

2026-03-30T13:25:28.000Z - 6 weeks ago

Clearmind Medicine completes treatment, follow-up in CMND-100 trial

Mar 30, 2026, 8:32 AM EDT - 6 weeks ago

Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

2026-03-27T11:51:31.000Z - 6 weeks ago

Clearmind files patent application in India for psychedelic-based compounds

Mar 27, 2026, 7:32 AM EDT - 6 weeks ago

Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders

2026-03-19T12:56:01.000Z - 7 weeks ago

Clearmind Medicine reports successful ongoing treatment in CMND-100 trial

Mar 19, 2026, 8:45 AM EDT - 7 weeks ago

Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder

2026-03-17T13:22:24.000Z - 2 months ago

Clearmind Medicine granted six therapy patents in Hong Kong

Mar 17, 2026, 9:15 AM EDT - 2 months ago

Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies

Mar 16, 2026, 7:30 AM EDT - 2 months ago

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

2026-03-13T11:52:33.000Z - 2 months ago

Clearmind Medicine announces Hong Kong patent filing for depression therapy

SPRC

Mar 13, 2026, 7:45 AM EDT - 2 months ago

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

Mar 11, 2026, 9:07 AM EDT - 2 months ago

Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results

Mar 11, 2026, 7:30 AM EDT - 2 months ago

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Mar 10, 2026, 8:59 AM EDT - 2 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SPRC

Mar 4, 2026, 7:30 AM EST - 2 months ago

Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval

Feb 19, 2026, 1:05 PM EST - 2 months ago

Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?

Feb 9, 2026, 8:17 AM EST - 3 months ago

Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial

Feb 6, 2026, 7:55 AM EST - 3 months ago

Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI

Feb 3, 2026, 8:00 AM EST - 3 months ago

Excellent Achievements for Clearmind's Proprietary MEAI that was Included in U.S. Congress' Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments

Jan 20, 2026, 4:20 PM EST - 4 months ago

Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025

Jan 14, 2026, 8:55 AM EST - 4 months ago

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100

Dec 31, 2025, 9:10 AM EST - 4 months ago

Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 24, 2025, 9:15 AM EST - 4 months ago

Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth

Dec 16, 2025, 8:45 AM EST - 5 months ago

Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100

Dec 12, 2025, 8:32 AM EST - 5 months ago

Clearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Dec 12, 2025, 6:32 AM EST - 5 months ago

Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Dec 10, 2025, 4:15 PM EST - 5 months ago

Clearmind Medicine Announces 1-for-40 Reverse Share Split

Dec 5, 2025, 5:00 PM EST - 5 months ago

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Dec 2, 2025, 7:57 AM EST - 5 months ago

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Dec 1, 2025, 8:56 AM EST - 5 months ago

Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial

Nov 25, 2025, 7:17 AM EST - 6 months ago

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Nov 24, 2025, 8:51 AM EST - 6 months ago

Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review

Nov 20, 2025, 6:01 AM EST - 6 months ago

Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

Nov 19, 2025, 8:30 AM EST - 6 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

SPRC

Nov 18, 2025, 8:56 AM EST - 6 months ago

Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 17, 2025, 7:55 AM EST - 6 months ago

Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 13, 2025, 8:54 AM EST - 6 months ago

Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Nov 12, 2025, 6:25 AM EST - 6 months ago

Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment

Nov 10, 2025, 8:07 AM EST - 6 months ago

Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Nov 6, 2025, 4:02 PM EST - 6 months ago

Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Nov 5, 2025, 6:55 AM EST - 6 months ago

Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing

Oct 30, 2025, 7:55 AM EDT - 6 months ago

Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 28, 2025, 8:08 AM EDT - 7 months ago

Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar

Oct 27, 2025, 9:22 AM EDT - 7 months ago

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement

Oct 21, 2025, 7:25 AM EDT - 7 months ago

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Oct 20, 2025, 7:41 AM EDT - 7 months ago

Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Sep 25, 2025, 7:40 AM EDT - 8 months ago

Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies